格莱姆巴妥木单抗ELISA检测试剂盒

Glembatumumab ELISA Kit

货号：RB9T37017344

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37017344

中文名称
格莱姆巴妥木单抗ELISA检测试剂盒

英文名称
Glembatumumab ELISA Kit

应用
ELISA

登录号
Q14956

靶标
格莱姆巴妥木单抗酶联免疫检测试剂盒

检测方法
Colorimetric

灵敏度
0.156 μg/ml

检测范围
0.31-5 μg/mL

回收率
80-120%

样本类型
Plasma, Serum

检测类型
Quantitative

背景信息

Glembatumumab (CR011) is a fully human IgG2 monoclonal antibody (mAb) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB, or osteoactivin). It was designed to linke to monomethyl auristatin E (MMAE) via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate (ADC) termed glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG’ s Xeloda (capecitabine).

别名

CDX-011 (DOX), CR011, glembatumumab vedotin (ADC), 1020264-78-1

稳定性和储存

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate

storage condition.

运输条件

2-8 ℃

For Research Use Only.